A molecular marker for identifying Brucella Rev.1 vaccine strains and its application
By designing specific primer and probe combinations and utilizing singleton and duplex PCR methods, the problem of differentiating Brucella Rev.1 vaccine strain from other Brucella strains was solved, achieving high sensitivity and high specificity in detection and supporting infection monitoring and eradication in vaccine-immunized populations.
Patent Information
- Application Number
- CN202611531103.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-30
- Publication Date
- 2026-11-10
AI Technical Summary
Existing technologies make it difficult to effectively distinguish Brucella Rev.1 vaccine strains from other Brucella strains, leading to difficulties in identifying and eliminating sources of infection in vaccine-immunized populations and affecting human and animal health.
Specific primer and probe combinations were designed, and singlet and doublet PCR methods were used to identify Brucella Rev.1 vaccine strains. The specific amplification curves of primers and probes were used to distinguish between vaccine strains and wild-type strains, and a quantitative PCR detection method was established.
It achieves highly sensitive, specific, and reproducible detection of Brucella Rev.1 vaccine strain, accurately distinguishing between vaccine strain and wild-type strain, thus improving the sensitivity and ease of detection.
Smart Images

Figure CN123063535A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of molecular biology technology, specifically relating to a molecular marker for identifying Brucella vaccine strains and its application in the preparation of quantitative PCR detection kits. Background Technology
[0002] Brucellosis is caused by Brucella bacteria (Brucella multocida). Brucella Brucellosis is a zoonotic infectious disease caused by brucellosis. Its pathogenesis is complex and difficult to cure once infected, making vaccination the primary means of prevention. my country began developing brucellosis vaccines as early as the early 1950s. After vaccination, both humans and animals develop brucellosis-like symptoms, leading to difficulties in differentiation. Furthermore, commonly used serological testing methods cannot effectively distinguish between vaccine-induced antibodies and wild-type virus infection antibodies, making it difficult to accurately identify and remove infected individuals from immunized herds. This results in the long-term presence of the source of infection, continuously threatening the health of humans and animals. Researchers have conducted extensive targeted studies on methods for distinguishing between vaccine strains and wild-type strains, such as the kit for identifying PRV gE-deficient vaccine strains and wild-type strains proposed in patent CN201010146353.4. Wild-type strains are prevalent, highly pathogenic native pathogens that cause disease in their hosts. Vaccine strains are typically artificially passaged, attenuated, or genetically engineered strains that retain immunogenicity but have extremely low pathogenicity. Therefore, identifying wild-type and vaccine strains based on their genetic differences is the most effective method.
[0003] Brucellosis vaccines are biological agents used to prevent infectious diseases in animals such as cattle, sheep, and pigs caused by Brucella. The main types include live brucellosis vaccine for cattle (strain A19), live brucellosis vaccine for pigs (strain S2), and live brucellosis vaccine for sheep (strains M5-90Δ26, BA0711, and Rev.1). Currently, several research teams in China are actively promoting the development of Brucella gene-marked vaccines and their supporting differential diagnostic technologies. However, due to the long development cycle from research and validation to approval for production and application of new vaccines, existing brucellosis vaccines remain the mainstream products in China. Therefore, developing efficient differential diagnostic technologies for existing mainstream vaccines is particularly important. Summary of the Invention
[0004] In view of the shortcomings of the existing technology, the purpose of this invention is to provide a molecular marker for identifying Brucella Rev.1 vaccine strains, which can effectively distinguish Brucella Rev.1 vaccine strains from other Brucella strains.
[0005] A second objective of this invention is to provide primers and probes compatible with the said molecular markers, and a kit containing said primers and probes.
[0006] The technical solution for achieving the above-mentioned objective of this invention is as follows: A molecular marker for identifying Brucella Rev.1 vaccine strains, wherein the molecular marker is a Brucella Rev.1 vaccine strain-specific deletion nucleotide sequence of 3537 bp as shown in SEQ ID NO.7, and a Brucella Rev.1 vaccine strain-specific nucleotide sequence of 600 bp as shown in SEQ ID NO.8.
[0007] The molecular marker SEQ ID NO.7 is a specific deletion molecular marker for the Brucella Rev.1 vaccine strain, and other wild-type strains and vaccine strains have this fragment; the molecular marker SEQ ID NO.8 is a specific nucleotide sequence for the Rev.1 vaccine strain, and other wild-type strains and vaccine strains do not have the complete sequence.
[0008] The primer and probe combination used for amplifying the molecular marker of claim 1, wherein the sequence of the upstream primer is shown in SEQ ID NO.1, the sequence of the downstream primer is shown in SEQ ID NO.2, and the probe is the Rev.1 probe with the nucleotide sequence SEQ ID NO.5, wherein the 5' end of the Rev.1 probe is labeled with the fluorescent group ROX, and the 3' end is labeled with the quencher group BHQ1. Or The upstream primer sequence is shown in SEQ ID NO.3, the downstream primer sequence is shown in SEQ ID NO.4, and the probe is the NRev.1 probe with the nucleotide sequence SEQ ID NO.6. The NRev.1 probe is labeled with the fluorescent group FAM at its 5' end and the quencher group BHQ2 at its 3' end.
[0009] Using this primer and probe combination, Brucella vaccine strains or wild-type strains can be identified by singleton PCR.
[0010] The present invention further proposes a primer and probe combination for amplifying the aforementioned molecular marker, wherein the upstream primer is one of the two sequences shown in SEQ ID NO.1 and SEQ ID NO.3, and the downstream primer is one of the two sequences shown in SEQ ID NO.2 and SEQ ID NO.4.
[0011] The probes are Rev.1 probe and NRev.1 probe. The nucleotide sequence of Rev.1 probe is SEQ ID NO.5, and the nucleotide sequence of NRev.1 probe is SEQ ID NO.6. Rev.1 probe is labeled with the fluorescent group ROX at its 5' end and the quencher group BHQ1 at its 3' end. NRev.1 probe is labeled with the fluorescent group FAM at its 5' end and the quencher group BHQ2 at its 3' end.
[0012] A preferred embodiment of the present invention is a kit for singleton qPCR testing, comprising the primer combination and the probe.
[0013] The amplification system of the kit consists of 12.5 μL of Premix Ex Taq, 1.0 μL of the upstream primer shown in SEQ ID NO.3, 1.0 μL of the downstream primer shown in SEQ ID NO.4, 1.0 μL of the NRev.1 probe shown in SEQ ID NO.6, 4.5–7.5 μL of dd H2O, and 2.0 μL of template genomic DNA, or... The amplification system of the kit is 12.5 μL of Premix Ex Taq, 1.0 μL of the upstream primer shown in SEQ ID NO.1, 1.0 μL of the downstream primer shown in SEQ ID NO.2, 1.0 μL of the Rev.1 probe shown in SEQ ID NO.5, 4.5~7.5 μL of dd H2O, and 2.0 μL of template genomic DNA.
[0014] Furthermore, the kit determines the presence of a vaccine strain based on the amplification curve. When Rev.1 is used as a probe, the presence of an amplification curve indicates the presence of a wild-type strain or a Brucella vaccine strain other than Rev.1.
[0015] Another preferred embodiment of the present invention is a kit for dual qPCR, comprising the aforementioned primer and probe combination.
[0016] The amplification system of the kit consists of 12.5 μL of Premix Ex Taq, 1.0 μL each of the two upstream primers shown in SEQ ID NO.1 and SEQ ID NO.3, 1.0 μL each of the two downstream primers shown in SEQ ID NO.2 and SEQ ID NO.4, 1.0 μL each of the Rev.1 probe shown in SEQ ID NO.5 and the NRev.1 probe shown in SEQ ID NO.6, 4.5–7.5 μL of dd H2O, and 2.0 μL of template genomic DNA.
[0017] The kit makes a judgment based on the amplification curve, or the amplification curve and Ct value.
[0018] Furthermore, in the amplification system of the kit, the concentrations of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, Rev.1 and NRev.1 are independently 10~20 μM.
[0019] The kit determines the strain based on the amplification curve. If only the Rev.1 amplification curve of the first channel is displayed, the sample to be tested is the Brucella Rev.1 vaccine strain. If only the NRev.1 amplification curve of the second channel is displayed, the sample to be tested contains other strains of Brucella; if the Rev.1 and NRev.1 amplification curves of the first and second channels are displayed at the same time, the sample to be tested contains both Brucella Rev.1 vaccine strain and other strains of Brucella. The other Brucella strains are wild-type strains and Brucella vaccine strains other than Rev.1. The Brucella vaccine strains other than Rev.1 include one or more of BA0711, A19, M5-90, and S2. Using this dual qPCR kit, it is possible to identify not only samples containing only vaccine strains or only virulent strains, but also mixed samples containing both vaccine and virulent strains.
[0020] The instrument channel display colors can be manually set. For example, the first channel can be set to orange (Rev.1), and the second channel can be set to blue.
[0021] A quantitative PCR detection method for identifying Brucella Rev.1 vaccine strains or other Brucella strains using the aforementioned molecular markers includes the following steps: 1) Take tissue samples from the individual to be tested, extract DNA, and elute the DNA with elution buffer TE; 2) The obtained DNA sample was amplified by qPCR using primer combination and probe. The qPCR reaction program was 95 ℃ for 30 s, 95 ℃ for 5 s, 60 ℃ for 30 s, and the number of cycles was 40. 3) Make a judgment based on the amplification curve, or the amplification curve and Ct value.
[0022] This singleton qPCR kit is used for singleton PCR. In step 2), Rev.1 is used as the probe, and the probe concentration is 10-20 μM; the concentrations of the primers shown in SEQ ID NO.1 and SEQ ID NO.2 are independently 10-20 μM, and the concentration of the probe shown in Rev.1 is 10-20 μM; or N Rev.1 was used as the probe, with a concentration of 10–20 μM; the concentrations of the primers shown in SEQ ID NO.3 and SEQ ID NO.4 were independently 10–20 μM. In step 3), the amplification curve, or the amplification curve and Ct value, are used to determine whether the sample to be tested is Brucella vaccine strain Rev.1 or other Brucella strains. When Rev.1 is used as a probe, an orange amplification curve indicates the presence of a vaccine strain; when N Rev.1 is used as a probe, a blue amplification curve indicates the presence of a wild-type strain or Brucella vaccine strain other than Rev.1.
[0023] This dual qPCR kit is used for dual PCR. In step 2), qPCR amplification is performed using the primer set SEQ ID NO.1 + SEQ ID NO.2 and SEQ ID NO.3 + SEQ ID NO.4, and the Rev.1 and NRev.1 probes shown in the nucleotide sequences SEQ ID NO.5 and SEQ ID NO.6. In step 3), the amplification curve, or the amplification curve and Ct value, are used to determine whether the sample to be tested is Brucella Rev.1 vaccine strain or other Brucella strains.
[0024] Step 1) The tissue sample can be whole blood, swabs, abortion products, bacteria, etc., preferably whole blood samples or abortion products, among which whole blood samples are stable and more suitable for DNA extraction.
[0025] In the qPCR reaction system, Rev.1 is used as the probe only. If an orange amplification curve appears, the sample to be tested is Brucella Rev.1 vaccine strain; or, NRev.1 is used as the probe only. If a blue amplification curve appears, the sample to be tested is other Brucella strains.
[0026] This study focuses on the Brucella Rev.1 vaccine strain widely used in my country. Comparative genomics was used to identify its specific vaccine-deleted molecular marker gene, which can effectively distinguish the Brucella Rev.1 vaccine strain from other Brucella strains. Based on this marker gene, specific primers and probes were designed, and a quantitative PCR (qPCR) detection method that can accurately distinguish the Rev.1 vaccine strain was successfully established. The establishment of this method effectively solves the problem of the lack of rapid identification tools in production practice, providing key technical support for infection monitoring and precise eradication in vaccine-immunized populations.
[0027] The beneficial effects of this invention are as follows: The molecular marker proposed in this invention for identifying Brucella Rev.1 vaccine strains is a specific deletion molecular marker for Brucella Rev.1 vaccine strains. Primers, probes, and kits were designed using this gene, providing a new detection method for the identification and diagnosis of Brucella Rev.1 vaccine strains. This detection method has good specificity, high sensitivity, and good repeatability, making up for the shortcomings of the prior art.
[0028] The quantitative PCR detection method for Brucella Rev.1 vaccine strain established based on this missing gene has higher sensitivity. The detection results of this invention are clearly displayed through amplification curves of different colors, and the detection sensitivity is improved; the lowest detection limit of dual qPCR can reach 10. 1 copies / μL.
[0029] The detection kit of the present invention can intuitively determine the positive or negative status of a sample through amplification curves and Ct values, making it simpler and more convenient. Attached Figure Description
[0030] To more clearly illustrate the technical solutions in this invention or the prior art, the accompanying drawings used in the description of the embodiments or the prior art will be briefly introduced below.
[0031] Figure 1 This is the BLAST result of the Brucella Rev.1 vaccine strain specific deletion fragment in Example 1 of the present invention.
[0032] Figure 2 This is an electrophoresis image of PCR amplification of the Brucella Rev.1 vaccine strain-specific deletion gene in Example 1 of the present invention, wherein M: DL2000 DNA Marker, 1: negative control, 2-3: primers for Rev.1 vaccine strain, and 4-5: primers for NRev.1 wild-type virus strain.
[0033] Figure 3 These are PCR amplification electrophoresis images of two recombinant plasmids in Example 1 of this invention, where M: DL2000 Marker, 1-2: pMD-Rev.1, 3: negative control, and 4-5: pMD-NRev.1.
[0034] Figure 4 This is the result of establishing the Rev.1-ROX singlet qPCR standard curve in Example 2 of this invention.
[0035] Figure 5 This is the result of establishing the NRev.1-FAM singlet qPCR standard curve in Example 2 of this invention.
[0036] Figure 6These are the results of the Rev.1-ROX singlet qPCR specificity experiment in Example 2 of this invention. Wherein, 1 and 1-1 are the Rev.1 vaccine strain DNA amplification curves, 3-5 are the negative control amplification curves, and 6-12 are the DNA amplification curves of Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella, Escherichia coli, Salmonella, and Corynebacterium pseudotuberculosis. 3-12 represents the amplification results of the negative control (3-5) and the amplification results of the DNA of Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella, Escherichia coli, Salmonella, and Corynebacterium pseudotuberculosis (6-12). No S-type amplification curves were produced in 3-12.
[0037] Figure 7 These are the results of the NRev.1-FAM singlet qPCR specificity experiment in Example 2 of this invention. Wherein, 2 and 2-1 are DNA amplification curves of other strains of NRev.1 Brucella, 3-5 are amplification curves of the negative control, and 6-12 are DNA amplification curves of Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella, Escherichia coli, Salmonella, and Corynebacterium pseudotuberculosis.
[0038] Figure 8 This is the result of the Rev.1-ROX singlet qPCR sensitivity experiment in Example 2 of this invention.
[0039] Figure 9 This is the result of the NRev.1-FAM singlet qPCR sensitivity experiment in Example 2 of this invention.
[0040] Figure 10 This is the result of the Rev.1-ROX singlet qPCR repeatability experiment in Example 2 of this invention.
[0041] Figure 11 This is the result of the repeatability experiment of NRev.1-FAM single qPCR in Example 2 of the present invention.
[0042] Figure 12 This is the result of establishing the dual qPCR standard curve in Example 3 of the present invention, wherein curve 1 is Rev.1-ROX representing Brucella Rev.1 vaccine strain, and curve 2 is NRev.1-FAM representing other Brucella strains.
[0043] Figure 13 These are the results of the specificity and identification effect of the double qPCR experiment in Example 3 of this invention. 1, 1-1 is the Brucella Rev.1 vaccine strain. 2, 2-1 are other Brucella NRev.1 strains. 3-5 are negative controls, and 6-12 are Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella, Escherichia coli, Salmonella, and Corynebacterium pseudotuberculosis.
[0044] Figure 14These are the results of the dual qPCR sensitivity experiment in Example 3 of this invention, with concentrations from left to right being 10... 5 10 4 10 3 10 2 10 1 The orange curve represents the Brucella Rev.1 vaccine strain, while the blue curve represents NRev.1, which represents other Brucella strains.
[0045] Figure 15 These are the results of the duplex qPCR repeatability experiment in Example 3 of this invention, with concentrations from left to right being 10... 6 10 5 10 4 The orange curve represents the Brucella Rev.1 vaccine strain, while the blue curve represents NRev.1, which represents other Brucella strains. Detailed Implementation
[0046] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the invention.
[0047] Unless otherwise defined, all scientific and technical terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art.
[0048] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0049] The Rev.1 vaccine strain DNA and the genomic DNA of Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella multocida, Escherichia coli, Salmonella, and Corynebacterium pseudotuberculosis described in this invention were preserved by the Preventive Veterinary Laboratory of Inner Mongolia Agricultural University.
[0050] Unless otherwise specified, all instruments, reagents, and consumables used in this invention were purchased commercially. The first channel of the PCR instrument was set to orange, and the second channel was set to blue.
[0051] Example 1
[0052] The whole genome sequences of Brucella Rev.1 vaccine strain and Brucella meliogene wild-type strain M28 were compared and analyzed using gene alignment software. Differentially expressed genes between Brucella Rev.1 vaccine strain and wild-type strain were screened, and candidate differentially expressed molecular marker genes were selected for comparison and analysis in the NCBI database. Figure 1Based on the BLAST results, the specific deletion gene of Brucella Rev.1 vaccine strain and the 600bp vaccine strain-specific gene were identified. Primers and probes were designed based on these sites. The identified Brucella Rev.1 vaccine strain-specific deletion gene (SEQ ID NO.7) and Rev.1 vaccine strain-specific gene (SEQ ID NO.8) were used as target genes for PCR, and standard positive recombinant plasmids were prepared. Based on the gene alignment results, Rev.1 DNA and DNA from non-Rev.1 strains (other Brucella strains) were used as templates in subsequent experiments. Wild-type strain M28 can cover most other Brucella strains, so wild-type strain DNA was used as a template. Wild-type strain M28 DNA was biosynthesized by Shanghai Sangon Biotech Co., Ltd.
[0053] Blast comparison of the gene fragment missing from the Rev.1 vaccine strain showed that the gene fragment shown in SEQ ID NO.7 could cover gene fragments of common Brucella vaccine strains (such as S2, A19, M5-90, BA0711) and naturally occurring virulent strains (such as M28, 16M, etc.).
[0054] In the text, NRev.1 means: N means not, and NRev.1 means except for Rev.1.
[0055] The steps for identifying the Brucella Rev.1 vaccine strain-specific deletion sites—wild-virus-specific genes and vaccine strain-specific genes—are as follows: The complete chromosome I sequence of the Brucella Rev.1 vaccine strain and the complete chromosome I sequence of Brucella M28 strain were compared using software. The results showed that the Brucella Rev.1 vaccine strain has a 3537bp specific deletion compared to other Brucella vaccine strains and wild-virus strains. This deletion site can be used as a specific marker sequence for the Brucella wild-virus strain. Simultaneously, the Rev.1 vaccine strain has a 600bp specific sequence compared to other Brucella vaccine strains and wild-virus strains. This specific site can be used as a specific marker sequence for the Brucella Rev.1 vaccine strain. Based on these sites, subsequent primer and probe design and the establishment of differential diagnostic methods were carried out. The specific procedures are as follows.
[0056] 1.1 Test Methods 1.1.1 Primer and Probe Design and Screening: Based on the specific deletion sites of the Brucella Rev.1 vaccine strain, primers and probes were designed to effectively distinguish the Brucella Rev.1 vaccine strain from the wild-type strain. The synthesis of primers and probes was completed by Shanghai Biotech Co., Ltd. Three pairs of primers were designed for SEQ ID NO.7 and SEQ ID NO.8 respectively. The second and third pairs of primers showed non-specific amplification and low specificity. The first pair of primers was preferred. The nucleotide sequence is shown below.
[0057] Rev.1 primer F: 5′-TTGCCTGCCGAAAGGAACA-3′ (SEQ ID NO.1) Rev.1 primer R: 5′-ATCGCGCACCGTTTTAAGC-3′ (SEQ ID NO.2) NRev.1 primer F: CTGAAGGACAAGGACGGCAAT (SEQ ID NO.3) NRev.1 primer R: GCGGTCCACCACCAGATAAC (SEQ ID NO.4) Rev.1 probe: 5′-ROX- CGCGCTGCTGGTATGGGATAAGGA-BHQ1-3′ (SEQ ID NO.5) NRev.1 probe: 5′-FAM-TCGGCTTCACCAGGCCAAACCC-BHQ2 (SEQ ID NO.6) In the probe specificity optimization experiment, two pairs of probes were designed based on the screened genes SEQ ID NO.7 and SEQ ID NO.8 for specificity verification, as shown in Table 1. qPCR amplification verification of the two pairs of probes revealed that probes VacqP-Probe1 and BruqP-Probe1 exhibited significant specificity and no cross-reactivity, while probes VacqP-Probe2 and BruqP-Probe2 showed cross-reactivity and were therefore not selected (see Table 2). Finally, VacqP-Probe1 and BruqP-Probe1 were determined to be the optimal probe sequences.
[0058] Table 1. Vaccines and wild-type virus qPCR probes
[0059] Table 2 Probe Specificity Verification
[0060] 1.1.2 PCR amplification of the target gene: Using genomic DNA from Brucella mesenteriae Rev.1 vaccine strain and Brucella NRev.1 strain as templates, the target gene fragment was amplified using the designed specific primers (SEQ ID NO. 1~4), and its specificity was verified. The PCR amplification reaction conditions were: pre-denaturation at 95 ℃ for 5 min, denaturation at 95 ℃ for 50 s, annealing at 57 ℃ for 50 s, extension at 72 ℃ for 30 s, for 35 cycles, followed by 72 ℃ for 10 min. Bands of 134 bp and 171 bp were amplified, respectively. After PCR amplification, agarose gel electrophoresis was performed for detection.
[0061] 1.1.3 PCR product recovery and ligation of pMD19-T Simple vector: The target gene was recovered according to the instructions of the Tiangen gel recovery kit. 4 μL of the recovered gel product and 1 μL of pMD19-T vector were mixed in a 200 μL PCR tube, and 5 μL of Solution I was added. Ligation was carried out at room temperature for 12 h to obtain the ligation product.
[0062] 1.1.4 Transformation of recombinant plasmids: 12 h later, 50 μL of Trans1-T1 competent cells thawed from ice were added to a new 1.5 mL sterile, enzyme-free centrifuge tube. The ligation product was added to the system and incubated on ice for 30 min, followed by a 30 s incubation at 42°C for 32°C, and then an ice incubation for 2 min. 500 μL of antibiotic-free liquid LB medium was added to the 1.5 mL centrifuge tube, and the culture was incubated at 37°C for 8 h by shaking at 200 r / min. 100 μL of the culture was then evenly spread onto solid LB medium containing Amp in a clean bench and incubated at 37°C for 16 h under constant temperature and humidity.
[0063] 1.1.5 PCR identification of recombinant plasmids: Single colonies were picked from LB solid medium and inoculated into liquid medium containing 1% Amp. The culture was incubated at 37 ℃ and 200 r / min for 12–16 h. PCR amplification was performed using 3 μL of bacterial culture as a template, with a negative control included. The PCR products were detected by 1.0% agarose gel electrophoresis.
[0064] 1.1.6 Recombinant plasmid sequencing: Take 2 mL of bacterial culture and extract plasmids according to the instructions of the Axygen plasmid extraction kit. After extraction, take an appropriate amount of recombinant plasmid and send it to BGI for sequencing.
[0065] 1.1.7 Plasmid Concentration Measurement: For plasmids with correct sequencing results, the plasmid concentration was measured using a NanoDrop nucleic acid concentration analyzer. The concentration was determined according to the formula: Copy Number = (6.02 × 10⁻⁶) / (6.02 × 10⁻⁶) * ... 23 ×concentration×10 -9 The unit was converted to copies / μL, and the initial concentrations of the two plasmids were adjusted to 1×10⁻⁶. 9 copies / μL.
[0066] 1.2 Experimental Results 1.2.1 Detection of Brucella Rev.1 vaccine strain and wild-type strain-specific genes: The genome sequence of the Brucella Rev.1 vaccine strain was compared with that of Brucella M28 strain. The comparison results showed that the Brucella Rev.1 vaccine strain contained a 3537 bp specific deletion site and a 600 bp Rev.1 vaccine strain-specific gene. PCR amplification was performed using primers designed based on the above sites, and the results were detected by 1% agarose gel electrophoresis. The results are shown in the figure below. Figure 2 Then, gel recovery and sequencing were performed.
[0067] The results showed that two target bands, 134 bp and 171 p, could be amplified using Brucella Rev.1 vaccine strain DNA and NRev.1 strain DNA as templates, respectively. The PCR amplification products were sent to BGI for sequencing, and the sequencing results showed that the amplified product sequence was consistent with the target sequence.
[0068] 1.2.2 Recombinant plasmid PCR identification: After the target fragment was ligated into the pMD19-T vector, it was transformed into competent cells and cultured on solid medium for 12–16 h. Two single colonies were picked and inoculated into LB liquid medium, cultured for 12–16 h, and then PCR amplified using the bacterial culture as a template. The results were then analyzed by 1% agarose gel electrophoresis and product sequencing. pMD-Rev.1 and pMD-NRev.1 amplified bands of 134 bp and 171 bp, respectively, which were consistent with the size of the target band. (See attached figure). Figure 3 Sequencing results showed that the amplified product sequence was consistent with the target sequence.
[0069] 1.2.3 Recombinant plasmid concentration: The plasmid concentration was determined using a NanoDrop nucleic acid concentration analyzer, according to the formula: Copy number = (6.02 × 10⁻⁶) / (6.02 × 10⁻⁶)². 23 ×concentration×10 -9 The units were converted to copies / μL by converting ((cloning vector length + product size)×660】. The results are shown in Table 3.
[0070] Table 3. DNA concentration and copy number of the two recombinant plasmids
[0071] Example 2 The recombinant plasmid prepared in Example 1 was used as a standard positive template for subsequent experiments. Two single-tube qPCR detection methods for Brucella were established, and the qPCR reaction system was optimized to reduce the mutual interference between primers and probes, so as to obtain a stable and reliable qPCR differential diagnosis method. This lays the foundation for the subsequent differential diagnosis of Brucella Rev.1 vaccine strain and wild-type strain using single-tube qPCR.
[0072] 2.1 Experimental Methods 2.1.1 Optimization of singleton qPCR reaction conditions: The PCR program was: 95 ℃ for 30 s, 95 ℃ for 5 s, 60 ℃ for 30 s, with a cycle number of 40.
[0073] The checkerboard method was used to optimize the reaction system. With qPCR reaction conditions and a primer / probe concentration of 10 μmol / L as fixed conditions, the upstream and downstream primer and probe amounts for Rev.1-ROX and N Rev.1-FAM qPCR reaction systems were adjusted. Primers and probes were diluted at 1:10, 1:20, 1:30, 1:40, and 1:50 from the 10 μmol / L base concentration, and the checkerboard method was used to optimize the reaction system. The optimal reaction amounts were determined by the primer and probe amounts that resulted in the lowest Ct value and highest sensitivity for the same concentration of positive template.
[0074] 2.1.2 Establishment of two singlet qPCR standard curves The concentrations of recombinant plasmids constructed from the nucleic acid marker sequences of Brucella Rev.1 vaccine strain and NRev.1 strain were adjusted to 1×10⁻⁶, respectively. 9 Copies / μL, diluted proportionally to 1×10 using ddH2O. 8 copies / μL, 1×10 7 copies / μL, 1×10 6 copies / μL, 1×10 5 Copies / μL, using recombinant plasmid as a template, with 3 replicates for each dilution, sample type set to Standard, were used for qPCR amplification, resulting in two qPCR amplification curves targeting Rev.1 and NRev.1 sequences respectively. The singlet qPCR reaction program was 95 ℃ for 30 s, 95 ℃ for 5 s, 60 ℃ for 30 s, with 40 cycles. In this qPCR reaction, the primer and probe concentrations were fixed at 10 μmol / L, and the amount of Rev.1-ROX and NRev.1-FAM primers added was 1.0 μL, and the amount of probe added was 1.0 μL.
[0075] Rev.1-ROX qPCR reaction system: Premix Ex Taq (Probe qPCR) 12.5 μL, upstream primer (SEQ ID NO.1) 1.0 μL, downstream primer (SEQ ID NO.2) 1.0 μL, probe (SEQ ID NO.5) 1.0 μL, ddH2O 7.5 μL, template genomic DNA 2.0 μL.
[0076] qPCR reaction system for NRev.1-FAM: Premix Ex Taq12.5 μL of (Probe qPCR), 1.0 μL of upstream primer (SEQ ID NO.3), 1.0 μL of downstream primer (SEQ ID NO.4), 1.0 μL of probe (SEQ ID NO.6), 7.5 μL of ddH2O, and 2.0 μL of template genomic DNA.
[0077] 2.1.3 Singleton qPCR Specificity Assay Using two optimized qPCR reaction conditions, Rev.1 vaccine strain DNA and NRev.1 strain DNA were used as positive controls, and genomic DNA extracted from Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella multocida, Escherichia coli, Salmonella, and Corynebacterium pseudotuberculosis were used as templates for the reaction group. dd H2O was used as the negative control group. qPCR detection was performed with three replicates in each group. The presence or absence of amplification curves in the qPCR reaction was observed to evaluate the specificity of the detection method.
[0078] 2.1.4 Singleton qPCR Sensitivity Assay Two recombinant plasmids were respectively added from 10 5 copies / μL to 10 1 10-fold serial dilutions were performed using copies / μL of the recombinant plasmid. Using the diluted plasmid as a template, three replicates were set up for each concentration gradient of the two qPCR reactions. dd H2O was used as a negative control to evaluate the sensitivity of the two qPCR reactions. Conventional PCR was then performed using qPCR primers with the same copy number of the recombinant plasmid as a template to compare the sensitivity of qPCR and conventional PCR.
[0079] 2.1.5 Single qPCR repeatability experiment The concentration of each recombinant plasmid was selected as 1×10⁻⁶. 6 copies / μL, 1×10 5 copies / μL, 1×10 4 Using copies / μL as the positive template, and with optimized singleton reaction conditions, six replicates were performed for each template concentration. The experiment was repeated after changing to different batches of Premix Ex Taq (Probe qPCR). The coefficient of variation of Ct values within and between groups was calculated to evaluate the repeatability of singleton qPCR.
[0080] 2.2 Experimental Results 2.2.1 Results of optimization of singleton qPCR reaction conditions In the qPCR reaction, the primer and probe concentrations were fixed at 10 μmol / L. The optimal primer and probe amounts were optimized, revealing that Rev.1-ROX and NRev.1-FAM exhibited the best amplification curves with a primer amount of 1.0 μL. With the primer amount fixed at 1.0 μL, the amplification curves showed that Rev.1-ROX showed the best amplification curve with a probe amount of 1.0 μL, while NRev.1-FAM showed the best amplification curve with a probe amount of 1.0 μL. The final optimized reaction is shown below: Optimized qPCR reaction system (Rev.1-ROX): Premix Ex Taq (Probe qPCR) 12.5 μL, upstream primer 1.0 μL, downstream primer 1.0 μL, probe 1.0 μL, dd H2O 7.5 μL, template genomic DNA 2.0 μL.
[0081] Optimized qPCR reaction system (NRev.1-FAM): Premix Ex Taq (Probe qPCR) 12.5 μL, upstream primer 1.0 μL, downstream primer 1.0 μL, probe 1.0 μL, dd H2O 7.5 μL, template genomic DNA 2.0 μL.
[0082] 2.2.2 Establishment of the Standard Curve respectively with 1×10 9 copies / μL, 1×10 8 copies / μL, 1×10 7 copies / μL, 1×10 6 copies / μL, 1×10 5 Using recombinant plasmids pMD-Rev.1 and pMD-NRev.1 (copies / μL) as templates, a qPCR standard curve was constructed under optimized reaction conditions. The linear regression equation for Rev.1-ROX was y = 39.205 - 3.405x, and the amplification efficiency of the standard curve was 96.70%. 2 The linear regression equation for NRev.1-FAM is y = 42.095 - 3.479x, the standard curve amplification efficiency is 93.91%, and R0 is 1.000. 2 The value is 0.999. All values are within the valid range and can be used for subsequent quantitative detection. The standard curve is as follows: Figure 4 , Figure 5 As shown.
[0083] 2.2.3 Specificity Experiment Results: qPCR amplification was performed using Rev.1 vaccine strain DNA, NRev.1 strain DNA, and Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella, Escherichia coli, Salmonella, and Corynebacterium pseudotuberculosis as templates to verify the specificity of the experiment. The results showed that the Rev.1-ROX group showed an orange positive amplification curve when using Rev.1 vaccine strain DNA as the amplification template alone; the NRev.1-FAM group showed a blue positive amplification curve when using NRev.1 strain as the amplification template.
[0084] Specific results such as Figure 6 , Figure 7 As shown in the figure, neither of the two primer probe negative controls produced an amplification curve, and there was no cross-reactivity with Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella multocida, Escherichia coli, Salmonella, or Corynebacterium pseudotuberculosis.
[0085] 2.2.4 Sensitivity Experiment Results: Sensitivity experiment results showed that the amplification curves of Rev.1-ROX and NRev.1-FAM groups were within 10... 5 ~10 1 At copies / μL, amplification curves were generated for each replicate well, with Rev.1-ROX at 10 1 All three parallel wells with a template concentration of copies / μL produced valid results. NRev.1-FAM at 10 1 All three parallel wells with a template concentration of copies / μL produced valid results. Sensitivity experiment results are as follows: Figure 8 , Figure 9 As shown.
[0086] 2.2.5 Repeatability Experiment Results: Rev.1-ROX and NRev.1-FAM primers and probes were used at 1×10⁻⁶ ppm. 6 copies / μL, 1×10 5 copies / μL, 1×10 4 Using recombinant plasmids of copies / μL as templates, and different batches of Premix Ex were used... Taq (Probe qPCR) Repeat experiments: Data from the two singleton qPCR repeatability experiments are shown in Table 4; qPCR curves are shown below. Figure 10 and Figure 11 The coefficients of variation (CV%) within both singlet qPCR groups were less than 0.5%, and the coefficients of variation between both groups were less than 0.5%, indicating good reproducibility.
[0087] Table 4. Repeatability test data for two singleton qPCR methods
[0088] Example 3 Both singleton qPCR methods described in Example 2 can be used for Brucella detection, and the reaction efficiency of each primer and probe has been verified to be good when used alone. To achieve simultaneous differential diagnosis of Brucella Rev.1 vaccine strain and other strains, the four primers (SEQ ID NO.1 to SEQ ID NO.4) and two probes from Example 2 should be added to the reaction system: Rev.1 probe: 5′-CGCGCTGCTGGTATGGGATAAGGA-3′, and NRev.1 probe: 5′-TCGGCTTCCACCAGGCCAAACCC-3′. This allows for the simultaneous differential diagnosis of Brucella Rev.1 vaccine strain and other Brucella strains using single-tube qPCR.
[0089] 3.1 Experimental Methods 3.1.1 Optimization of Duplex qPCR Reaction Conditions: The reaction system was optimized using a checkerboard method. With qPCR reaction conditions and a concentration of 10 μmol / L for both primers and probes as fixed conditions, the upstream and downstream primer and probe amounts were adjusted for both Rev.1-ROX and NRev.1-FAM duplex qPCR reaction systems. The checkerboard method was used to simultaneously optimize the primer and probe amounts in the duplex qPCR. A total reaction volume of 25 μL was used, with the Premix Ex... Taq (Probe qPCR) 12.5 μL, DNA template 2 μL, primer and probe working concentration 10 μmol / L, annealing / extension temperature 60℃, reaction program 95℃ 30 s; 95℃ 5 s; 60℃ 30 s, fluorescence acquisition; 40 cycles. During optimization, another primer-probe pair was fixed as the optimal singleton qPCR condition. The amount of the target primer pair added (equal volumes upstream and downstream) and the amount of probe added were used as two factors, with 5 levels set: 0.2, 0.4, 0.6, 0.8, and 1.0 μL, respectively. A 5×5 checkerboard matrix was constructed, resulting in 25 combinations. The optimal combination was determined by the following criteria: lower Ct value, earlier plateau phase of the amplification curve, higher endpoint fluorescence intensity, balanced signal in both channels, lower coefficient of variation in replicates, and no amplification in the negative control.
[0090] In this duplex PCR reaction system, the concentration of both primers and probes was 10 μmol / L. The duplex qPCR reaction program was 95℃ for 30 s, 95℃ for 5 s, and 60℃ for 30 s, with a cycle count of 40. The reaction system was: Premix Ex Taq(ProbeqPCR) 12.5 μL, upstream primer (SEQ ID NO.1 + SEQ ID NO.3) 1.0 + 1.0 μL, downstream primer (SEQ ID NO.2 + SEQ ID NO.4) 1.0 + 1.0 μL, probe (Rev.1 + NRev.1) 1.0 + 1.0 μL, dd H2O 4.5 μL, template genomic DNA 2.0 μL.
[0091] 3.1.2 Establishment of standard curve: The concentrations of both recombinant plasmids were adjusted to 1×10⁻⁶. 9 After mixing in equal proportions (copies / μL), perform serial dilutions of 10-fold each, yielding 1×10⁻⁶ copies / μL. 8 copies / μL, 1×10 7 copies / μL, 1×10 6 copies / μL, 1×10 5 Mixed standard recombinant plasmids of two copies / μL were used as templates. 2 μL of the mixed plasmids were added to each well. dd H2O was used as a negative control. Each concentration was tested in triplicate. The instrument reaction well sample type was set to "Standard". The target fragment was amplified and fluorescence signal was detected using the optimized reaction system and reaction program to obtain a double qPCR amplification standard curve.
[0092] 3.1.3 Duplex qPCR Specificity Experiment: Two standard positive mixed plasmids were used as the positive control group, and dd H2O was used as the negative control group. Genomic DNA extracted from Rev.1 vaccine strain, NRev.1 strain, Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella multocida, Escherichia coli, Salmonella, and Corynebacterium pseudotuberculosis were used as templates. Each template was used in 3 replicate wells. The specificity and discrimination effect of the established duplex qPCR detection method were evaluated.
[0093] 3.1.4 Dual qPCR sensitivity test: Two 1×10 9 Standard positive recombinant plasmids of copies / μL were mixed in equal proportions and serially diluted 10-fold to obtain 1×10⁻⁶ copies / μL. 9 ~1×10 1 Nine concentrations of dual-mixed standard positive plasmids at various concentrations (copies / μL) were used, and 1×10⁻⁶ copies / μL of these plasmids were selected through a 10-fold serial dilution. 5 ~1×10 1 Five different concentrations of mixed recombinant plasmids (copies / μL) were used as templates, with three replicate wells for each gradient. A negative control group using dd H2O as a template was added to test the sensitivity of this method.
[0094] 3.1.5 Duplex qPCR repeatability experiment: Select 1×10 6 copies / μL, 1×10 5 copies / μL, 1×10 4 Two equal-proportion plasmid mixtures (copies / μL) were used as templates, with three replicates per well for each concentration. The experiment was repeated after 7 days, and after 21 days, different batches of Premix Ex were used. Taq The repeatability of this method was evaluated by performing (Probe qPCR) experiments.
[0095] 3.1.6 Double qPCR differential diagnostic test for clinical blood samples: 1) Prepare 2 mL centrifuge tubes. Take 300 μL of whole sheep blood from 64 samples and lyse the red blood cells according to the instructions of the blood DNA extraction kit using the lysis method to extract DNA. Finally, elute the DNA with 50 μL of elution buffer TE. Use 2 μL as a template for dual qPCR detection.
[0096] 2) Amplification of the reaction system as described in Section 3.1.1.
[0097] 3) Determine whether the sample to be tested is Brucella vaccine strain Rev.1 or other Brucella strains based on the amplification curve, or the amplification curve and Ct value; if only an orange Rev.1 amplification curve appears, the sample to be tested contains Brucella Rev.1 vaccine strain; if only a blue NR Rev.1 amplification curve appears, the sample to be tested contains other Brucella strains; if both orange and blue Rev.1 and NR Rev.1 amplification curves appear simultaneously, the sample to be tested contains both Brucella Rev.1 vaccine strain and other Brucella strains.
[0098] 3.2 Experimental Results 3.2.1 Results of establishing the dual qPCR standard curve Using optimized reaction conditions, a duplex qPCR standard curve was obtained by repeating experiments with two different concentrations of mixed plasmids as DNA templates. Figure 12 As shown. The linear regression equation for Rev.1-ROX is y=41.266-3.442x, and the linear regression equation for NRev.1-FAM is y=38.492-3.338x. The standard curve results show that the amplification efficiency E of the Rev.1-ROX standard curve is 95.21%, R... 2 The amplification efficiency E of the NRev.1-FAM standard curve was 99.35%, and the R value was 0.999. 2 The value was 1.000. The results of the double qPCR replicate assay showed high repeatability and good linearity, making it suitable for subsequent sample identification and analysis.
[0099] 3.2.2 Results of the specificity and identification effect of dual qPCR Two standard positive mixed plasmids were used as the positive control group, and dd H2O was used as the negative control group. Genomic DNA extracted from Rev.1 vaccine strain, NRev.1 strain, Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella multocida, Escherichia coli, Salmonella, and Corynebacterium pseudotuberculosis was used as templates for dual qPCR detection. The results showed that Rev.1 vaccine strain DNA showed an orange amplification curve, while NRev.1 strain showed a blue amplification curve. Genomic DNA from Bifidobacterium, Clostridium perfringens, Corynebacterium pyogenes, Pasteurella multocida, Escherichia coli, Salmonella, and Corynebacterium pseudotuberculosis did not show any amplification curves, indicating negative results. Figure 13 As shown in the figure. The results indicate that this method has good specificity and can distinguish between Rev.1 vaccine strains and other Brucella strains.
[0100] 3.2.3 Results of Dual qPCR Sensitivity Experiment The template concentration was detected under optimized reaction conditions of 1×10⁻⁶. 5 copies / μL, 1×10 4 copies / μL, 1×10 3 copies / μL, 1×10 2 copies / μL, 1×10 1 The sensitivity of dual qPCR was evaluated using a mixture of copies / μL of recombinant plasmid, and the amplification curves are shown below. Figure 14 As shown in the figure. Experimental results show that the detection limit of Rev.1-ROX and NRev.1-FAM can reach as low as 1×10⁻⁶. 1 The high sensitivity (copies / μL) demonstrates that the established dual qPCR differential diagnostic method meets the requirements for clinical sample testing.
[0101] 3.2.4 Results of Dual qPCR Repeatability Experiment At a concentration of 1×10 6 copies / μL, 1×10 5 copies / μL, 1×10 4 Using a mixed recombinant plasmid (copies / μL) as a template, reproducible within-group and between-group experiments were performed, with different batches of the reaction enzyme used. The results showed that the coefficient of variation (CV) of the Ct values within and between groups was less than 0.5%, indicating that the dual qPCR detection method established in this study has good reproducibility. The results are shown in Table 5 and... Figure 15 .
[0102] Table 5 Results of intra- and inter-group repeatability tests of dual qPCR
[0103] 3.2.5 Double qPCR Differential Diagnostic Test for Clinical Blood Samples Using this method, 108 clinical samples were tested, with 8 negative samples and 100 positive samples. Among them, 10 samples were positive for Rev.1 vaccine strain, 85 samples were positive for other Brucella strains, and 5 samples were mixed infection samples.
[0104] This invention discovered a specific deletion site of 3537 bp and a 600 bp Rev.1 vaccine-specific gene fragment in the Brucella Rev.1 vaccine strain, a site that has not been previously studied and reported. Based on this gene site, specific primers and probes were designed, and by utilizing the more specific Taq Man probe, the Brucella Rev.1 vaccine strain was identified.
[0105] Although the present invention has been described above through embodiments, those skilled in the art should understand that any improvements and modifications made to the present invention without departing from its spirit and essence should fall within the protection scope of the present invention.
Claims
1. A molecular marker for identifying Brucella Rev.1 vaccine strains, characterized in that, The molecular markers are the Brucella Rev.1 vaccine strain-specific deletion nucleotide sequence with a length of 3537 bp shown in SEQ ID NO.7, and the Brucella Rev.1 vaccine strain-specific nucleotide sequence with a length of 600 bp shown in SEQ ID NO.
8.
2. A primer and probe combination for amplifying the molecular marker of claim 1, characterized in that, The upstream primer sequence is shown in SEQ ID NO.1, the downstream primer sequence is shown in SEQ ID NO.2, and the probe is the Rev.1 probe with the nucleotide sequence SEQ ID NO.
5. The 5' end of the Rev.1 probe is labeled with the fluorescent group ROX, and the 3' end is labeled with the quencher group BHQ1; or The upstream primer sequence is shown in SEQ ID NO.3, the downstream primer sequence is shown in SEQ ID NO.4, and the probe is the NRev.1 probe with the nucleotide sequence SEQ ID NO.
6. The NRev.1 probe is labeled with the fluorescent group FAM at its 5' end and the quencher group BHQ2 at its 3' end.
3. A primer and probe combination for amplifying the molecular marker of claim 1, characterized in that, The upstream primers are the two types shown in SEQ ID NO.1 and SEQ ID NO.3, and the downstream primers are the two types shown in SEQ ID NO.2 and SEQ ID NO.
4. The probes are Rev.1 probe and NRev.1 probe. The nucleotide sequence of Rev.1 probe is SEQ ID NO.5, and the nucleotide sequence of NRev.1 probe is SEQ ID NO.
6. The 5' end of Rev.1 probe is labeled with the fluorescent group ROX, and the 3' end is labeled with the quencher group BHQ1. The 5' end of NRev.1 probe is labeled with the fluorescent group FAM, and the 3' end is labeled with the quencher group BHQ2.
4. A kit for singleton qPCR testing, comprising the primer and probe combination as described in claim 2.
5. The reagent kit according to claim 4, characterized in that, The amplification system of the kit is 12.5 μL of Premix ExTaq, 1.0 μL of the upstream primer shown in SEQ ID NO.3, 1.0 μL of the downstream primer shown in SEQ ID NO.4, 1.0 μL of the NRev.1 probe shown in SEQ ID NO.6, 4.5~7.5 μL of dd H2O, and 2.0 μL of template genomic DNA; or The amplification system of the kit is 12.5 μL of Premix Ex Taq, 1.0 μL of the upstream primer shown in SEQ ID NO.1, 1.0 μL of the downstream primer shown in SEQ ID NO.2, 1.0 μL of the Rev.1 probe shown in SEQ ID NO.5, 4.5~7.5 μL of dd H2O, and 2.0 μL of template genomic DNA.
6. The reagent kit according to claim 4, characterized in that, The kit determines the presence of a vaccine strain based on the amplification curve. When Rev.1 is used as the probe, the presence of an amplification curve indicates the presence of a wild-type strain or a Brucella vaccine strain other than Rev.
1.
7. A kit for dual qPCR comprising the primer and probe combination of claim 3.
8. The reagent kit according to claim 7, characterized in that, The amplification system of the kit consists of 12.5 μL of Premix ExTaq, 1.0 μL each of the two upstream primers shown in SEQ ID NO.1 and SEQ ID NO.3, 1.0 μL each of the two downstream primers shown in SEQ ID NO.2 and SEQ ID NO.4, 1.0 μL each of the Rev.1 probe shown in SEQ ID NO.5 and the NRev.1 probe shown in SEQ ID NO.6, 4.5–7.5 μL of dd H2O, and 2.0 μL of template genomic DNA.
9. The reagent kit according to claim 8, characterized in that, In the amplification system of the kit, the concentrations of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, Rev.1 and NRev.1 are independently 10~20 μM.
10. The kit according to claim 7, characterized in that, The kit determines the strain based on the amplification curve. If only the Rev.1 amplification curve of the first channel is displayed, the sample to be tested is the Brucella Rev.1 vaccine strain. If only the NRev.1 amplification curve of the second channel is displayed, the sample to be tested contains other strains of Brucella; if the Rev.1 and N Rev.1 amplification curves of the first and second channels are displayed at the same time, the sample to be tested contains both Brucella Rev.1 vaccine strain and other strains. The other Brucella strains are wild-type strains and Brucella vaccine strains other than Rev.1, including one or more of BA0711, A19, M5-90, and S2.
Citation Information
Patent Citations
Kit for authenticating deletion of vaccine strain and wild strain of PRVgE
CN101831506A
